SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-070920
Filing Date
2020-03-12
Accepted
2020-03-12 07:32:06
Documents
4
Period of Report
2020-03-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d897785d8k.htm 8-K 27143
2 EX-99.1 d897785dex991.htm EX-99.1 64886
3 EX-99.2 d897785dex992.htm EX-99.2 15057
4 GRAPHIC g897785dsp10.jpg GRAPHIC 4190
  Complete submission text file 0001193125-20-070920.txt   114537
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 20707155
SIC: 2834 Pharmaceutical Preparations